A monocyte-TNF-endothelial activation axis in sickle transgenic mice: Therapeutic benefit from TNF blockade

American Journal of Hematology

Volumn 92, Issue 11, 2017, Pages 1119-1130

  Solovey, Anna ^a   Somani, Arif ^a   Belcher, John D ^a   Milbauer, Liming ^a   Vincent, Lucile ^a   Pawlinski, Rafal ^b   Nath, Karl A ^c   Kelm, Robert J ^d   Mackman, Nigel ^b   O'Sullivan, M Gerard ^e   Gupta, Kalpna ^a   Vercellotti, Gregory M ^a   Hebbel, Robert P ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c MAYO CLINIC   (United States)

^d UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^e UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANAKINRA; ANDROGRAPHOLIDE; CURCUMIN; EARLY GROWTH RESPONSE FACTOR 1; ETANERCEPT; GAMMA INTERFERON; HEMOGLOBIN; HISTONE DEACETYLASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLIXIMAB; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MEVINOLIN; MONOCYTE CHEMOTACTIC PROTEIN 1; SALAZOSULFAPYRIDINE; SMOOTH MUSCLE ACTIN; THROMBOPLASTIN; TUMOR NECROSIS FACTOR; VASCULAR CELL ADHESION MOLECULE 1; AUTACOID; BIOLOGICAL MARKER; EGR1 PROTEIN, MOUSE; MONOCLONAL ANTIBODY; PROTEIN KINASE INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL OCCLUSION; CELL ACTIVATION; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HEART RIGHT VENTRICLE PRESSURE; HISTOPATHOLOGY; LIVER INJURY; LONG TERM CARE; MALE; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SICKLE CELL ANEMIA; STAINING; THROMBOCYTE COUNT; TREATMENT DURATION; ANEMIA, SICKLE CELL; ANIMAL; ANTAGONISTS AND INHIBITORS; BONE MARROW TRANSPLANTATION; CELL AGGREGATION; DEFICIENCY; DISEASE MODEL; DRUG EFFECTS; ENDOTHELIUM CELL; GENETICS; HEART FUNCTION TEST; HUMAN; IMMUNOLOGY; KNOCKOUT MOUSE; METABOLISM; MOLECULARLY TARGETED THERAPY; MONOCYTE; MONONUCLEAR CELL; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE; VASCULAR ENDOTHELIUM;

ANEMIA, SICKLE CELL; ANIMALS; ANTIBODIES, MONOCLONAL; BIOMARKERS; BONE MARROW TRANSPLANTATION; CELL AGGREGATION; DISEASE MODELS, ANIMAL; EARLY GROWTH RESPONSE PROTEIN 1; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; ETANERCEPT; HEART FUNCTION TESTS; HUMANS; INFLAMMATION MEDIATORS; LEUKOCYTES, MONONUCLEAR; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; MOLECULAR TARGETED THERAPY; MONOCYTES; NF-KAPPA B; PHENOTYPE; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION; THROMBOPLASTIN; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR CELL ADHESION MOLECULE-1;

EID: 85026484344     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.24856     Document Type: Article

References (55)

1. Hebbel RP, Osarogiagbon R, Kaul D. The endothelial biology of sickle cell disease: inflammation and a chronic vasculopathy. Microcirculation. 2004;11(2):129–151.
2. Hebbel RP. Ischemia-reperfusion injury in sickle cell anemia: relationship to acute chest syndrome, endothelial dysfunction, arterial vasculopathy, and inflammatory pain. Hematol Oncol Clin North Am. 2014;28(2):181–198.
3. Belcher JD, Chen C, Nguyen J, et al. Heme triggers TLR4 signaling leading to endothelial cell activation and vaso-occlusion in murine sickle cell disease. Blood. 2014;123(3):377–390.
4. Setty BN, Betal SG, Zhang J, Stuart MJ. Heme induces endothelial tissue factor expression: potential role in hemostatic activation in patients with hemolytic anemia. J Thromb Haemost. 2008;6(12):2202–2209.
5. Belcher JD, Marker PH, Weber JP, Hebbel RP, Vercellotti GM. Activated monocytes in sickle cell disease: potential role in the activation of vascular endothelium and vaso-occlusion. Blood. 2000;96(7):2451–2459.
6. Wun T, Cordoba M, Rangaswami A, Cheung AW, Paglieroni T. Activated monocytes and platelet-monocyte aggregates in patients with sickle cell disease. Clin Lab Haematol. 2002;24(2):81–88.
7. Selvaraj SK, Giri RK, Perelman N, Johnson C, Malik P, Kalra VK. Mechanism of monocyte activation and expression of proinflammatory cytochemokines by placenta growth factor. Blood. 2003;102(4):1515–1524.
8. Perelman N, Selvaraj SK, Batra S, et al. Placenta growth factor activates monocytes and correlates with sickle cell disease severity. Blood. 2003;102(4):1506–1514.
9. Sloma I, Zilber MT, Charron D, Girot R, Tamouza R, Gelin C. Upregulation and atypical expression of the CD1 molecules on monocytes in sickle cell disease. Hum Immunol. 2004;65(11):1370–1376.
10. Zennadi R, Chien A, Xu K, Batchvarova M, Telen MJ. Sickle red cells induce adhesion of lymphocytes and monocytes to endothelium. Blood. 2008;112(8):3474–3483.
11. Marcal LE, Dias-da-Motta PM, Rehder J, et al. Up-regulation of NADPH oxidase components and increased production of interferon-gamma by leukocytes from sickle cell disease patients. Am J Hematol. 2008;83(1):41–45.
12. Brittain JE, Knoll CM, Ataga KI, Orringer EP, Parise LV. Fibronectin bridges monocytes and reticulocytes via integrin alpha4beta1. Br J Haematol. 2008;141(6):872–881.
13. Chaar V, Picot J, Renaud O, et al. Aggregation of mononuclear and red blood cells through an {alpha}4{beta}1-Lu/basal cell adhesion molecule interaction in sickle cell disease. Haematologica. 2010;95(11):1841–1848.
14. Kollander R, Solovey A, Milbauer LC, Abdulla F, Kelm RJ, Jr, Hebbel RP. Nuclear factor-kappa B (NFkappaB) component p50 in blood mononuclear cells regulates endothelial tissue factor expression in sickle transgenic mice: implications for the coagulopathy of sickle cell disease. Transl Res. 2010;155(4):170–177.
15. Safaya S, Steinberg MH, Klings ES. Monocytes from sickle cell disease patients induce differential pulmonary endothelial gene expression via activation of NF-kappaB signaling pathway. Mol Immunol. 2012;50(1–2):117–123.
16. Setty BN, Key NS, Rao AK, et al. Tissue factor-positive monocytes in children with sickle cell disease: correlation with biomarkers of haemolysis. Br J Haematol. 2012;157(3):370–380.
17. Ragab SM, Soliman MA. Tissue factor-positive monocytes expression in children with sickle cell disease: clinical implication and relation to inflammatory and Coagulation Markers. Blood Coagul Fibrinolysis. 2016;27(8):862–869.
18. Sprague AH, Khalil RA. Inflammatory cytokines in vascular dysfunction and vascular disease. Biochem Pharmacol. 2009;78(6):539–552.
19. Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther. 2008;117(2):244–279.
20. Van Hauwermeiren F, Vandenbroucke RE, Libert C. Treatment of TNF mediated diseases by selective inhibition of soluble TNF or TNFR1. Cytokine Growth Factor Rev. 2011;22(5–6):311–319.
21. Schmidt EP, Yang Y, Janssen WJ, et al. The pulmonary endothelial glycocalyx regulates neutrophil adhesion and lung injury during experimental sepsis. Nat Med. 2012;18(8):1217–1223.
22. Gao X, Xu X, Belmadani S, et al. TNF-alpha contributes to endothelial dysfunction by upregulating arginase in ischemia/reperfusion injury. Arterioscler Thromb Vasc Biol. 2007;27(6):1269–1275.
23. Crabtree MJ, Channon KM. Synthesis and recycling of tetrahydrobiopterin in endothelial function and vascular disease. Nitric Oxide. 2011;25(2):81–88.
24. Swerlick RA, Eckman JR, Kumar A, Jeitler M, Wick TM. Alpha 4 beta 1-integrin expression on sickle reticulocytes: vascular cell adhesion molecule-1-dependent binding to endothelium. Blood. 1993;82(6):1891–1899.
25. Kaul DK, Fabry ME, Nagel RL. Microvascular sites and characteristics of sickle cell adhesion to vascular endothelium in shear flow conditions: pathophysiological implications. Proc Natl Acad Sci U S A. 1989;86(9):3356–3360.
26. Fujita M, Mason RJ, Cool C, Shannon JM, Hara N, Fagan KA. Pulmonary hypertension in TNF-alpha-overexpressing mice is associated with decreased VEGF gene expression. J Appl Physiol (Physiol). 2002;93(6):2162–2170.
27. Berry M, Brightling C, Pavord I, Wardlaw A. TNF-alpha in asthma. Curr Opin Pharmacol. 2007;7(3):279–282.
28. Vgontzas AN, Zoumakis E, Lin HM, Bixler EO, Trakada G, Chrousos GP. Marked decrease in sleepiness in patients with sleep apnea by etanercept, a tumor necrosis factor-alpha antagonist. J Clin Endocrinol Metab. 2004;89(9):4409–4413.
29. Bozkurt B, Kribbs SB, Clubb FJ, Jr., et al. Pathophysiologically relevant concentrations of tumor necrosis factor-alpha promote progressive left ventricular dysfunction and remodeling in rats. Circulation. 1998;97(14):1382–1391.
30. Tobinick E, Kim NM, Reyzin G, Rodriguez-Romanacce H, DePuy V. Selective TNF inhibition for chronic stroke and traumatic brain injury: an observational study involving 629 consecutive patients treated with perispinal etanercept. CNS Drugs. 2012;26(12):1051–1070.
31. Marchand F, Perretti M, McMahon SB. Role of the immune system in chronic pain. Nat Rev Neurosci. 2005;6(7):521–532.
32. Hess A, Axmann R, Rech J, et al. Blockade of TNF-a rapidly inhibits pain responses in the central nervous system. Proceedings of the National Academy of Sciences. 2011;108(9):3731–3736.
33. Belcher JD, Bryant CJ, Nguyen J, et al. Transgenic sickle mice have vascular inflammation. Blood. 2003;101(10):3953–3959.
34. Solovey A, Kollander R, Shet A, et al. Endothelial cell expression of tissue factor in sickle mice is augmented by hypoxia/reoxygenation and inhibited by lovastatin. Blood. 2004;104(3):840–846.
35. Peppel K, Crawford D, Beutler B. A tumor necrosis factor (TNF) receptor-IgG heavy chain chimeric protein as a bivalent antagonist of TNF activity. J Exp Med. 1991;174(6):1483–1489.
36. Mazzon E, Esposito E, Di Paola R, et al. Effect of tumour necrosis factor-alpha receptor 1 genetic deletion on carrageenan-induced acute inflammation: a comparison with etanercept. Clin Exp Immunol. 2008;153(1):136–149.
37. Luong BT, Chong BS, Lowder DM. Treatment options for rheumatoid arthritis: celecoxib, leflunomide, etanercept, and infliximab. Ann Pharmacother. 2000;34(6):743–760.
38. Kaul DK, Thangaswamy S, Suzuka SM, Fabry ME, Alan A. Wanderer and Hermann Gram Anti-interleukin-1B antibody-based therapy ameliorates endothelial activation and inflammation in sickle mice. Blood. 2001;118:848. [abstract]
39. Toldo S, Schatz AM, Mezzaroma E, et al. Recombinant human interleukin-1 receptor antagonist provides cardioprotection during myocardial ischemia reperfusion in the mouse. Cardiovasc Drugs Ther. 2012;26(3):273–276.
40. Pawlinski R, Pedersen B, Kehrle B, et al. Regulation of tissue factor and inflammatory mediators by Egr-1 in a mouse endotoxemia model. Blood. 2003;101(10):3940–3947.
41. Vincent L, Vang D, Nguyen J, et al. Mast cell activation contributes to sickle cell pathobiology and pain in mice. Blood. 2013;122(11):1853–1862.
42. Cruz JA, Bauer EM, Rodriguez AI, et al. Chronic hypoxia induces right heart failure in caveolin-1-/- mice. Am J Physiol Heart Circ Physiol. 2012;302(12):H2518–H2527.
43. Mackman N. Regulation of the tissue factor gene. FASEB J. 1995;9(10):883–889.
44. Pritchard MT, Nagy LE. Ethanol-induced liver injury: potential roles for egr-1. Alcohol Clin Exp Res. 2005;29(11 Suppl):146S–150S.
45. Joyce DA, Gimblett G, Steer JH. Targets of glucocorticoid action on TNF-alpha release by macrophages. Inflamm Res. 2001;50(7):337–340.
46. Parry GC, Mackman N. A set of inducible genes expressed by activated human monocytic and endothelial cells contain kappa B-like sites that specifically bind c-Rel-p65 heterodimers. J Biol Chem. 1994;269(33):20823–20825.
47. Hebbel RP, Vercellotti GM, Pace BS, et al. The HDAC inhibitors trichostatin A and suberoylanilide hydroxamic acid exhibit multiple modalities of benefit for the vascular pathobiology of sickle transgenic mice. Blood. 2010;115(12):2483–2490.
48. Robinson JC, Graham BB, Rouault TC, Tuder RM. The crossroads of iron with hypoxia and cellular metabolism. Implications in the pathobiology of pulmonary hypertension. Am J Respir Cell Mol Biol. 2014;51(6):721–729.
49. Rossol M, Meusch U, Pierer M, et al. Interaction between transmembrane TNF and TNFR1/2 mediates the activation of monocytes by contact with T cells. J Immunol. 2007;179(6):4239–4248.
50. Tavakkoli F, Nahavandi M, Wyche MQ, Perlin E. Plasma levels of TNF-alpha in sickle cell patients receiving hydroxyurea. Hematology. 2004;9(1):61–64.
51. Sarray S, Saleh LR, Lisa Saldanha F, Al-Habboubi HH, Mahdi N, Almawi WY. Serum IL-6, IL-10, and TNFalpha levels in pediatric sickle cell disease patients during vasoocclusive crisis and steady state condition. Cytokine. 2015;72(1):43–47.
52. Zeng Z, Duan Z, Zhang T, et al. Association between tumor necrosis factor-alpha (TNF-alpha) promoter −308 G/A and response to TNF-alpha blockers in rheumatoid arthritis: a meta-analysis. Mod Rheumatol. 2013;23(3):489–495.
53. Hoppe C, Klitz W, D'harlingue K, et al. Confirmation of an association between the TNF(-308) promoter polymorphism and stroke risk in children with sickle cell anemia. Stroke. 2007;38(8):2241–2246.
54. Chang Milbauer L, Wei P, Enenstein J, et al. Genetic endothelial systems biology of sickle stroke risk. Blood. 2008;111(7):3872–3879.
55. Yang WS, Han NJ, Kim JJ, Lee MJ, Park SK. TNF-α activates high-mobility group Box 1 - toll-like receptor 4 signaling pathway in human aortic endothelial cells. Cell Physiol Biochem. 2016;38(6):2139–2151.